Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate

Stopped The biological effect seen with natalizumab was not sufficient to warrant further development in RA.

Conditions

• Rheumatoid Arthritis

Interventions

• DRUG: natalizumab
• DRUG: placebo

Sponsor

Biogen

Collaborators

• [object Object]